DeepCure, Patent Granted in the US for Resistant Hypertension Treatment Device

[Asia Economy Reporter Hyungsoo Park] Medical device developer DeepCure announced on the 2nd that it has obtained a patent in the United States for a ‘Resistant Hypertension Treatment Renal Denervation (RDN) Device.’

The ‘Laparoscopic Renal Denervation’ procedure treats hypertension by blocking the sympathetic nerves located on the outer wall of the renal artery. Utilizing the patent, a device equipped with a radiofrequency (RF) electrode can be brought into contact with the renal artery via the laparoscopic method to block the sympathetic nerves. The RF energy emitted from the electrode is directly delivered to the sympathetic nerves to block them, enabling a safe procedure while preventing damage to the vascular endothelium.

Resistant hypertension is a condition where blood pressure remains uncontrolled despite taking three or more types of antihypertensive drugs. Currently, there is no treatment, and it often progresses to serious complications such as stroke and cardiovascular diseases, leading to premature death.

A DeepCure representative stated, "The catheter method pursued by existing medical device companies had limitations such as the risk of vascular endothelium damage and incomplete nerve blockage because RF energy was emitted inside the renal artery," adding, "The patented laparoscopic method emits RF energy from outside the renal artery, overcoming the limitations of the existing catheter method."

DeepCure has filed a total of 33 patents, including international patent applications (PCT), to secure intellectual property rights. Starting this year, it plans to enter major overseas markets such as the United States, Europe, China, and Japan using the PCT system.

This content was produced with the assistance of AI translation services.